{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:32:11Z","timestamp":1768926731322,"version":"3.49.0"},"reference-count":21,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.3892\/ol.2014.2820","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T03:49:53Z","timestamp":1419220193000},"page":"1239-1243","source":"Crossref","is-referenced-by-count":9,"title":["Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report"],"prefix":"10.3892","volume":"9","author":[{"given":"SHIGAO","family":"HUANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAZHENG","family":"DANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FUJUN","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEI","family":"WEI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUXIN","family":"MA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SONG","family":"QIAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QIANYUN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,12,22]]},"reference":[{"key":"key20180108102705_b1-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A","article-title":"A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography","volume":"89","author":"Bristow","year":"2000","journal-title":"Cancer"},{"key":"key20180108102705_b2-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/gyno.1999.5397","article-title":"Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival","volume":"74","author":"Parazzini","year":"1999","journal-title":"Gynecol Oncol"},{"key":"key20180108102705_b3-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ygyno.2007.01.028","article-title":"Pelvic and aortic lymph node metastasis in epithelial ovarian cancer","volume":"105","author":"Pereira","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"key20180108102705_b4-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1525-1438.2005.15356.x","article-title":"Future options for first-line therapy of advanced ovarian cancer","volume":"15","author":"Du Bois","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108102705_b5-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180108102705_b6-ol-09-03-1239","first-page":"882","article-title":"Neoadjuvant chemotherapy for ovarian cancer","volume":"39","author":"Onda","year":"2012","journal-title":"Gan To Kagaku Ryoho"},{"key":"key20180108102705_b7-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108102705_b8-ol-09-03-1239","first-page":"681","article-title":"A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer","volume":"27","author":"Mouratidou","year":"2007","journal-title":"Anticancer Res"},{"key":"key20180108102705_b9-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"4","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180108102705_b10-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gynor.2013.07.008","article-title":"Patterns of spread of clear cell ovarian cancer: Case report and case series","volume":"6","author":"Kumar","year":"2013","journal-title":"Gynecol Oncol Rep"},{"key":"key20180108102705_b11-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2006.07.034","article-title":"Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy","volume":"104","author":"Petit","year":"2007","journal-title":"Gynecologic Oncology"},{"key":"key20180108102705_b12-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1098-2388(200007\/08)19:1<11::AID-SSU3>3.0.CO;2-3","article-title":"Current management of epithelial ovarian carcinoma: a review","volume":"19","author":"Marsden","year":"2000","journal-title":"Semin Surg Oncol"},{"key":"key20180108102705_b13-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.11.022","article-title":"The diagnostic value of PET\/CT for primary ovarian cancer - a prospective study","volume":"105","author":"Risum","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20180108102705_b14-ol-09-03-1239","volume-title":"Annual Report on the Results of Treatment in Gynaecological Cancer","author":"FIGO-International Federation of Gynaecologists and Obstetricians Cancer Committee","year":"1979"},{"key":"key20180108102705_b15-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108102705_b16-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108102705_b17-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2005.03.003","article-title":"Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature","volume":"55","author":"Gadducci","year":"2005","journal-title":"Critl Rev Oncol Hematol"},{"key":"key20180108102705_b18-ol-09-03-1239","first-page":"CD005343","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","volume":"8","author":"Morrison","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108102705_b19-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/era.11.24","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions","volume":"11","author":"Onda","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180108102705_b20-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1048-891X.2004.014507.x","article-title":"Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: Life expectancy compared to women of an age-matched normal population","volume":"14","author":"Lambert","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108102705_b21-ol-09-03-1239","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ijrobp.2009.03.061","article-title":"Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin\/taxane chemotherapy for advanced ovarian cancer: phase I study","volume":"76","author":"Rochet","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2014.2820\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:19:06Z","timestamp":1515399546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2014.2820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,22]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,12,22]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.3892\/ol.2014.2820"],"URL":"https:\/\/doi.org\/10.3892\/ol.2014.2820","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,22]]}}}